Terms: = Prostate cancer AND CCND3, P30281, 896, ENSG00000112576 AND Treatment
33 results:
1. Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
Blas L; Shiota M; Tanegashima T; Tsukahara S; Ueda S; Mutaguchi J; Goto S; Kobayashi S; Matsumoto T; Inokuchi J; Eto M
Int J Urol; 2024 Apr; 31(4):404-408. PubMed ID: 38154806
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic Performance and Safety of Positron Emission Tomography with
Surasi DS; Eiber M; Maurer T; Preston MA; Helfand BT; Josephson D; Tewari AK; Somford DM; Rais-Bahrami S; Koontz BF; Bostrom PJ; Chau A; Davis P; Schuster DM; Chapin BF;
Eur Urol; 2023 Oct; 84(4):361-370. PubMed ID: 37414702
[TBL] [Abstract] [Full Text] [Related]
3. Optimal management of renal cell carcinoma in octogenarians: Retrospective analysis using updated Korean Renal Cell Carcinoma (KORCC) database.
Kim JK; Jung G; Kwak C; Jeong CW; Kang SH; Hong SH; Kim YJ; Chung J; Hwang EC; Kwon TG; Byun SS
PLoS One; 2023; 18(3):e0283483. PubMed ID: 36996119
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of adaptive strategies based on deformation vector field features for MR-guided adaptive radiotherapy of prostate cancer.
Xia WL; Liang B; Men K; Zhang K; Tian Y; Li MH; Lu NN; Li YX; Dai JR
Med Phys; 2023 Jun; 50(6):3573-3583. PubMed ID: 36583878
[TBL] [Abstract] [Full Text] [Related]
5. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in prostate cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513
[TBL] [Abstract] [Full Text] [Related]
6. cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic prostate cancer: A Multi-institute 15-year Experience.
Reddy D; Peters M; Shah TT; van Son M; Tanaka MB; Huber PM; Lomas D; Rakauskas A; Miah S; Eldred-Evans D; Guillaumier S; Hosking-Jervis F; Engle R; Dudderidge T; Hindley RG; Emara A; Nigam R; McCartan N; Valerio M; Afzal N; Lewi H; Orczyk C; Ogden C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU
Eur Urol; 2022 Apr; 81(4):407-413. PubMed ID: 35123819
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin D
Klin Onkol; 2021; 34(3):220-234. PubMed ID: 34362257
[TBL] [Abstract] [Full Text] [Related]
8. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin Denis
Ceska Gynekol; 2021; 86(3):220-234. PubMed ID: 34192880
[TBL] [Abstract] [Full Text] [Related]
9. Can
Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H
J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140
[TBL] [Abstract] [Full Text] [Related]
10. Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.
Yao L; Shou J; Wang S; Song Y; Fang H; Lu N; Tang Y; Chen B; Qi S; Yang Y; Jing H; Jin J; Yu Z; Li Y; Liu Y
Radiat Oncol; 2020 Oct; 15(1):231. PubMed ID: 33008404
[TBL] [Abstract] [Full Text] [Related]
11. Facility-Level Variation in Pelvic Lymphadenectomy During Radical prostatectomy and Effect on Overall Survival in Men with High-Risk prostate cancer.
Friedlander DF; Krimphove MJ; Cole AP; Tully KH; Lipsitz SR; Kibel AS; Kilbridge KL; Trinh QD
Ann Surg Oncol; 2020 Jun; 27(6):1929-1936. PubMed ID: 31848818
[TBL] [Abstract] [Full Text] [Related]
12. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.
Tom MC; Reddy CA; Smile TD; Zhang RX; Ciezki JP; Stephans KL; Mian OY; Klein EA; Campbell S; Ulchaker J; Angermeier K; Tendulkar RD
Brachytherapy; 2020; 19(1):43-50. PubMed ID: 31813740
[TBL] [Abstract] [Full Text] [Related]
13. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
[TBL] [Abstract] [Full Text] [Related]
14. Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.
Choi KH; Lee SR; Hong YK; Park DS
Asian J Androl; 2018; 20(3):270-275. PubMed ID: 29271399
[TBL] [Abstract] [Full Text] [Related]
15. Penile Rehabilitation Therapy Following Radical prostatectomy: A Meta-Analysis.
Liu C; Lopez DS; Chen M; Wang R
J Sex Med; 2017 Dec; 14(12):1496-1503. PubMed ID: 29122494
[TBL] [Abstract] [Full Text] [Related]
16. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
[TBL] [Abstract] [Full Text] [Related]
17. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract] [Full Text] [Related]
18. Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.
Gu J; Ren L; Wang X; Qu C; Zhang Y
Int J Clin Exp Pathol; 2015; 8(11):14034-9. PubMed ID: 26823716
[TBL] [Abstract] [Full Text] [Related]
19. Hypofractionated Helical Tomotherapy for Older Aged Patients With prostate cancer: Preliminary Results of a Phase I-II Trial.
Liu HX; Du L; Yu W; Cai BN; Xu SP; Xie CB; Ma L
Technol Cancer Res Treat; 2016 Aug; 15(4):546-54. PubMed ID: 26152749
[TBL] [Abstract] [Full Text] [Related]
20. Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines.
Eroğlu C; Seçme M; Bağcı G; Dodurga Y
Tumour Biol; 2015 Dec; 36(12):9437-46. PubMed ID: 26124008
[TBL] [Abstract] [Full Text] [Related]
[Next]
